根据一项自然研究,抗抑郁剂Vortoroxetine在与标准治疗相结合时,在治疗血浆瘤方面显示出潜力。 Antidepressant Vortioxetine shows potential in treating glioblastomas when combined with standard treatments, based on a Nature study.
Vortioxetine,经批准的抗抑郁剂,在治疗Glioblastimas-侵袭性脑肿瘤方面表现出出乎意料的希望,根据对自然的研究,其存活率仅为12-18个月。 Vortioxetine, an approved antidepressant, has shown unexpected promise in treating glioblastomas—aggressive brain tumors with a survival rate of just 12-18 months—according to a study in Nature. 当与诸如手术和化疗等标准治疗相结合时,它显示出良好的效果。 When combined with standard treatments like surgery and chemotherapy, it demonstrated good efficacy. 虽然沃替西汀安全且具有成本效益，但需要临床试验来确定适当的剂量和人体有效性，不建议自行用药。 While vortioxetine is safe and cost-effective, clinical trials are needed to determine proper dosages and effectiveness in humans, and self-medication is not recommended.